Diclofenac

also known as Diclofenac Sodium · Voltaren · Diclofenac Potassium · Solaraze · DSG · cataflam · DIC075V · Pennsaid · +48 more

Other / unclassified targets KMO, MYC, PPARG via inhibition

Developed for: osteoarthritis, knee · osteoarthritis · pulpitis · actinic keratosis · chronic pain syndrome · neuropathy, painful · osteoarthritis, hip · primary dysmenorrhea
+83 more
· breast cancer · cataract · cystoid macular edema · macular retinal edema · migraine disorder · osteoarthritis, hand · periapical periodontitis · acute apical periodontitis · acute pancreatitis · anal fistula · aphthous stomatitis · arthritic joint disease · benign neoplasm of skin · breast disorder · carpal tunnel syndrome · chronic periodontitis · COVID-19 · dental pulp disorder · diabetic retinopathy · disease of the tendon · dry eye syndrome · glaucoma · head and neck neoplasm · headache disorder · hemorrhoid · impacted teeth, multiple · intervertebral disk degenerative disorder · migraine with aura · migraine without aura · musculoskeletal system disorder · neurofibroma · neurofibromatosis type 1 · non-small cell lung carcinoma · pancreatitis · patellofemoral pain syndrome · photosensitivity disease · respiratory tract infectious disorder · rheumatoid arthritis · sciatica · senile cataract · subarachnoid hemorrhage · sunburn · temporomandibular joint dysfunction syndrome · tenosynovitis of foot and ankle · thrombophlebitis · tinea unguium · traumatic brain injury · urinary tract infection · urolithiasis · uveitis · akinetic mutism · alcohol dependence · ankylosing spondylitis · arthropathy · basal cell carcinoma · bicipital tenosynovitis · brain injury · cholecystitis · common bile duct disorder · complex regional pain syndrome type 1 · congenital patella dislocation, unilateral · de Quervain disease · dental pulp necrosis · diabetic macular edema · dysmenorrhea · epicondylitis · frozen shoulder · gastric ulcer · gout · Graves disease · hand-foot syndrome · otitis externa · pericardial effusion · pharyngitis · postherpetic neuralgia · pulmonary embolism · rotator cuff syndrome · skin cancer · synovial bursa disorder · temporomandibular joint disorder · ureterolithiasis · urinary tract obstruction · uterine inflammatory disease
Investigated by: Novartis · Cairo University · Organon and Co · Iroko Pharmaceuticals, LLC · Pfizer · Boehringer Ingelheim
+175 more
· Depomed · GlaxoSmithKline · Javelin Pharmaceuticals · Merck Sharp & Dohme LLC · Novartis Pharmaceuticals · Assiut University · Cerimon Pharmaceuticals · IBSA Institut Biochimique SA · Mallinckrodt · Montefiore Medical Center · Noven Pharmaceuticals, Inc. · PPD Development, LP · Sandoz · ZetrOZ, Inc. · Aga Khan University · Almirall, S.A. · Amzell · BDD Pharma Ltd · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Drug Delivery International Ltd · Food and Drug Administration (FDA) · Grünenthal GmbH · HALEON · HaEmek Medical Center, Israel · Hamad Medical Corporation · National Cancer Institute (NCI) · Novum Pharmaceutical Research Services · Nuvo Research Inc. · Pakistan Institute of Medical Sciences · University of Debrecen · University of Sao Paulo · Xanodyne Pharmaceuticals · A.O.U. Città della Salute e della Scienza · Actavis Inc. · Ain Shams University · Air Force Military Medical University, China · Al-Azhar University · Alabama Physical Therapy & Acupuncture · Albert Einstein College of Medicine · Amneal Pharmaceuticals, LLC · Anchen Pharmaceuticals, Inc · Anne Chang · Argentine Tennis Association · Armed Forces Institute of Dentistry, Pakistan · Arthritis Treatment Center, Maryland · Assumpta Nnenna Nweke · Ataturk University · Baskent University · Bezmialem Vakif University · British University In Egypt · Brown, Theodore R., M.D., MPH · CMH Multan Institute of Medical Sciences · Campbell Clinic · Chengdu University of Traditional Chinese Medicine · China Medical University Hospital · Clinic for Infectious Diseases, University Hospital Bern, Switzerland · Clinical Hospital Center, Split · Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. · Cross Research S.A. · Dalia Salah Saif · Danish Headache Center · Daré Bioscience, Inc. · Eduardo Barbosa Coelho · Eisai Inc. · Emory University · Encube Ethicals Pvt. Ltd. · Endo USA Inc., a Keenova Therapeutics Company · Eye Clinic Medic Zuljan Jukic · FPR Specialty Pharmacy · Farjad Zafar · Farmoquimica S.A. · Federal University of the Valleys of Jequitinhonha and Mucuri · Fidia Farmaceutici s.p.a. · all 181 on the full record

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	ZIPSOR	—	2021-05-25	fda.gov ↗
Label expansion	US (FDA)	VOLTAREN ARTHRITIS PAIN	—	2020-02-14	fda.gov ↗
Label expansion	US (FDA)	ZORVOLEX	—	2014-08-22	fda.gov ↗
Label expansions (2)	US (FDA)	VOLTAREN	—	1996-07-23 – 1998-02-25	fda.gov ↗
Approved	US (FDA)	VOLTAREN	—	1988-07-28	fda.gov ↗

Trials 225 · started per year

today

US approved 1988

19881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 07 trials
Phase 0	NCT07837284	Oct 2026 → Oct 2027 expected	osteoarthritis, knee	Florida State University	Not yet recruiting	No outcome recorded
Phase 0	NCT06500871	Aug 2024 → May 2025 overdue	pulpitis	Cairo University	Not yet recruiting	No outcome recorded
Phase 0	NCT06053411	Mar 2024 → Aug 2026 overdue	—	Washington State University	Recruiting	No outcome recorded
Phase 0	NCT05413096	Jun 2021 → Oct 2022	aphthous stomatitis	Al-Azhar University	Completed	No outcome recorded
Phase 0	NCT03145259	Apr 2017 → Aug 2019	—	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 0	NCT02485145	Jul → Dec 2015	osteoarthritis, hand	Transdermal Therapeutics, Inc.	Unknown	No outcome recorded
Phase 0	NCT01592019	Apr → Nov 2012	—	University of Florida	Completed	No outcome recorded
Phase 133 trials · 2 missed
Phase 1	NCT06510062	Jul → Sep 2024	—	ZetrOZ, Inc.	Completed	No outcome recorded
Phase 1	NCT05968482	Jul → Dec 2023	—	Amzell	Completed	No outcome recorded
Phase 1	NCT05752526	May → Oct 2023	primary dysmenorrhea	Daré Bioscience, Inc.	Completed	No outcome recorded
Phase 1	NCT05254574	Feb 2022 → May 2026 overdue	osteoarthritis	ZetrOZ, Inc.	Recruiting	No outcome recorded
Phase 1	NCT04882319	Jun 2021 → Mar 2022	osteoarthritis, knee	Noven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04900129	Dec 2020	COVID-19	Sher-E-Bangla Medical College	Completed	No outcome recorded
Phase 1	NCT04391842	Sep → Dec 2019	osteoarthritis, knee	ZetrOZ, Inc.	Completed	No outcome recorded
Phase 1	NCT04235426	Jan 2018 → Jan 2021	carpal tunnel syndrome	Dalia Salah Saif	Unknown	No outcome recorded
Phase 1	NCT04585321	Nov 2017 → May 2018	—	Fidia Farmaceutici s.p.a.	Completed	No outcome recorded
Phase 1	NCT03074162	Apr → Jun 2017	—	Boehringer Ingelheim	Completed	Missed primary
Phase 1	NCT03072485	Mar 2017 → Feb 2019	—	Anne Chang	Completed	No outcome recorded
Phase 1	NCT02714842	Mar → May 2016	—	BDD Pharma Ltd	Completed	No outcome recorded
Phase 1	NCT03766984	Jun 2015	—	Grünenthal GmbH	Completed	No outcome recorded
Phase 1	NCT02495831	May 2015	—	Zambon SpA	Completed	Missed primary
Phase 1	NCT02666846	Mar → May 2015	—	Futura Medical Developments Ltd.	Completed	No outcome recorded
Phase 1	NCT02361619	Feb 2015 → Sep 2016	—	Turku University Hospital	Completed	No outcome recorded
Phase 1	NCT02201238	Oct → Nov 2014	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02169154	Jun → Jul 2014	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02192203	Apr → Jul 2014	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02004301	Jan → Mar 2014	—	BDD Pharma Ltd	Completed	No outcome recorded
Phase 1	NCT01876615	Jul → Oct 2013	—	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT01742663	Oct 2012 → Jul 2013	actinic keratosis	Sun Pharmaceutical Industries, Inc.	Completed	No outcome recorded
Phase 1	NCT01596647	May 2012 → Jul 2014	neoplasm	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01202799	Sep → Nov 2010	—	Mallinckrodt	Completed	No outcome recorded
Phase 1	NCT01812538	May → Jul 2009	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT00805090	Dec 2008 → Mar 2009	chronic kidney disease, liver disorder	Javelin Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00548678	Oct → Nov 2007	—	Javelin Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00509743	Sep 2007 → Feb 2008	—	Javelin Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02171507	May → Jul 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00913887	Apr → May 1994	—	Sandoz	Completed	No outcome recorded
Phase 1	NCT00914160	Aug → Sep 1993	—	Sandoz	Completed	No outcome recorded
Phase 1	NCT00913224	Apr 1993	—	Sandoz	Completed	No outcome recorded
Phase 1	NCT00893854	—	cystoid macular edema, uveitis	Shahid Beheshti University of Medical Sciences	Unknown	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT06439251	Oct 2023 → Jun 2025	patellofemoral pain syndrome	University of Lahore	Completed	No outcome recorded
Phase 1/2	NCT03519152	Mar 2016 → May 2017	chronic periodontitis	Tatyasaheb Kore Dental College	Completed	No outcome recorded
Phase 222 trials · 4 met primary
Phase 2	NCT06731270	Apr 2025 → Jan 2027 expected	non-small cell lung carcinoma	Emory University	Recruiting	No outcome recorded
Phase 2	NCT06184685	Oct → Nov 2021	osteoarthritis, knee	Thammasat University	Completed	No outcome recorded
Phase 2	NCT04341402	May 2020 → Mar 2021	tinea unguium	William N Handelman	Unknown	No outcome recorded
Phase 2	NCT03949673	Apr 2019 → Aug 2020	osteoarthritis, hip, osteoarthritis, knee	Regeneron Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04591795	Jan 2018 → Oct 2020	osteoarthritis	Mr NARIN KAKATUM	Unknown	No outcome recorded
Phase 2	NCT03277066	Sep 2017 → Sep 2019	osteoarthritis, knee	Noven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT03825016	Aug 2017 → Jan 2020	—	Ain Shams University	Completed	No outcome recorded
Phase 2	NCT03090971	Feb → Mar 2017	neurofibroma, neurofibromatosis type 1	Fundação Educacional Serra dos Órgãos	Completed	No outcome recorded
Phase 2	NCT02424578	May 2015 → Apr 2016	—	Iroko Pharmaceuticals, LLC	Completed	No outcome recorded
Phase 2	NCT02598102	Apr → Aug 2015	—	Institute of Nephro Urology, Bangalore	Completed	No outcome recorded
Phase 2	NCT01812928	Mar → Aug 2013	—	Aga Khan University	Completed	No outcome recorded
Phase 2	NCT01706588	Jan → May 2013	—	IBSA Institut Biochimique SA	Completed	Met primary
Phase 2	NCT02417337	Aug 2012 → Aug 2014	pulpitis	University of Khartoum	Completed	No outcome recorded
Phase 2	NCT01939743	Oct 2011 → Sep 2012	prostate carcinoma	Aga Khan University	Completed	No outcome recorded
Phase 2	NCT01119898	Aug 2010 → Feb 2011	osteoarthritis, knee	Mallinckrodt	Completed	Met primary
Phase 2	NCT00985439	Sep → Dec 2009	—	Iroko Pharmaceuticals, LLC	Completed	Met primary
Phase 2	NCT00991861	Aug 2009 → Feb 2010	actinic keratosis	Almirall, S.A.	Completed	No outcome recorded
Phase 2	NCT00484120	Jun 2007 → Nov 2008	osteoarthritis, knee	Pharmos	Completed	No outcome recorded
Phase 2	NCT00601640	Jan 2007 → Feb 2010	benign neoplasm of skin	University of Arizona	Completed	No outcome recorded
Phase 2	NCT00371696	Dec 2001 → Dec 2003	osteoarthritis	University of Bristol	Completed	No outcome recorded
Phase 2	NCT02658799	Jan 2000 → Dec 2004	poisoning	Baskent University	Completed	No outcome recorded
Phase 2	NCT00242489	Jun 1998 → Feb 1999	osteoarthritis	Organon and Co	Completed	Met primary

Phase 2/37 trials
Phase 2/3	NCT07853664	Jan → Dec 2026 expected	—	Thamar University	Recruiting	No outcome recorded
Phase 2/3	NCT06207253	Nov → Dec 2025 overdue	dental pulp disorder	British University In Egypt	Recruiting	No outcome recorded
Phase 2/3	NCT03341260	Dec 2016 → Feb 2018	pulpitis	Cairo University	Completed	No outcome recorded
Phase 2/3	NCT02714699	Oct 2016 → Mar 2017	—	Assiut University	Completed	No outcome recorded
Phase 2/3	NCT03174860	Oct 2016 → Feb 2018	pulpitis	Cairo University	Completed	No outcome recorded
Phase 2/3	NCT03163420	Jul 2016 → Jul 2017	pulpitis	Cairo University	Unknown	No outcome recorded
Phase 2/3	NCT00276419	Jun 2005 → May 2009	breast disorder	Mayo Clinic	Terminated	No outcome recorded Stop: Business
Phase 359 trials · 9 met primary · 2 missed
Phase 3	NCT07145645	Apr 2026 → Sep 2027 expected	musculoskeletal system disorder	University of Calgary	Recruiting	No outcome recorded
Phase 3	NCT06693648	Feb → Dec 2025	osteoarthritis, knee	Amzell	Completed	No outcome recorded
Phase 3	NCT06731556	Dec 2024	—	Bezmialem Vakif University	Completed	No outcome recorded
Phase 3	NCT06561035	Sep 2024 → Dec 2027 expected	—	Campbell Clinic	Enrolling by invitation	No outcome recorded
Phase 3	NCT05312645	Dec 2023 → Aug 2024	headache disorder	Loma Linda University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT05626140	Sep 2021 → May 2022	sciatica	Pakistan Institute of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT04683627	Dec 2020 → Jul 2022	osteoarthritis, knee	Noven Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 3	NCT03597867	Apr → Jul 2018	—	University of Trieste	Completed	No outcome recorded
Phase 3	NCT03826550	Jan → Jun 2018	actinic keratosis	Encube Ethicals Pvt. Ltd.	Completed	No outcome recorded
Phase 3	NCT03714672	Aug 2017 → Mar 2018	—	Grünenthal GmbH	Completed	Met primary
Phase 3	NCT02700815	May 2016 → Jul 2017	—	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT02709590	Mar → Jun 2016	—	Assiut University	Completed	No outcome recorded
Phase 3	NCT02596451	Aug 2015 → Mar 2016	osteoarthritis, knee	Glenmark Pharmaceuticals Ltd. India	Completed	No outcome recorded
Phase 3	NCT02476422	Apr → Aug 2015	—	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT02752971	Feb 2015 → Feb 2016	—	Hospital Central Dr. Luis Ortega	Completed	No outcome recorded
Phase 3	NCT02339428	Jan 2015 → Oct 2016	anemia	University Hospital Rijeka	Completed	No outcome recorded
Phase 3	NCT02271854	Oct → Dec 2014	—	Novartis	Completed	No outcome recorded
Phase 3	NCT02121002	Apr → Oct 2014	osteoarthritis	Amneal Pharmaceuticals, LLC	Completed	No outcome recorded
Phase 3	NCT02194088	Apr → Nov 2014	—	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 3	NCT02068859	Jan 2014 → Jan 2015	chronic pain syndrome	FPR Specialty Pharmacy	Unknown	No outcome recorded
Phase 3	NCT02100670	Nov 2013 → Mar 2015	—	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01967550	Oct 2013 → May 2014	osteoarthritis, knee	Novartis	Completed	No outcome recorded
Phase 3	NCT01962987	Mar → Sep 2013	actinic keratosis	Actavis Inc.	Completed	Met primary
Phase 3	NCT01421433	May → Aug 2012	—	Farmoquimica S.A.	Unknown	No outcome recorded
Phase 3	NCT01511939	Feb 2012 → May 2013	blood coagulation disease, osteoarthritis, knee	Nathan Wei, MD, FACP, FACR	Completed	No outcome recorded
Phase 3	NCT01510912	Jan 2012 → Mar 2013	osteoarthritis	Iroko Pharmaceuticals, LLC	Completed	No outcome recorded
Phase 3	NCT01462435	Oct 2011 → Feb 2012	—	Iroko Pharmaceuticals, LLC	Completed	Met primary
Phase 3	NCT01461369	Oct 2011 → Mar 2012	osteoarthritis	Iroko Pharmaceuticals, LLC	Completed	Mixed
Phase 3	NCT01456611	Sep 2011 → Apr 2012	osteoarthritis, knee	Anchen Pharmaceuticals, Inc	Completed	No outcome recorded
Phase 3	NCT01300312	Feb → Jun 2011	—	Eisai Inc.	Completed	No outcome recorded
Phase 3	NCT01272934	Jan → Aug 2011	tenosynovitis of foot and ankle	Novartis	Completed	No outcome recorded
Phase 3	NCT01272947	Jan → Jul 2011	—	Novartis	Completed	No outcome recorded
Phase 3	NCT01265602	Nov 2010 → Mar 2012	actinic keratosis	Almirall, S.A.	Completed	No outcome recorded
Phase 3	NCT01255423	Nov 2010 → Jun 2011	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00943098	Sep 2009 → Mar 2010	—	IBSA Institut Biochimique SA	Completed	No outcome recorded
Phase 3	NCT00931866	Apr → Sep 2009	—	Cerimon Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00869180	Feb → Jun 2009	—	Cerimon Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00869063	Feb → Jul 2009	—	Cerimon Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00726388	Sep 2008 → May 2009	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00546832	Oct 2007 → Oct 2008	osteoarthritis, knee	Mika Pharma GmbH	Completed	No outcome recorded
Phase 3	NCT00507026	Jul 2007 → Oct 2008	—	Pfizer	Completed	Met primary
Phase 3	NCT00426621	Nov 2006 → Jun 2007	osteoarthritis, knee	Novartis	Completed	No outcome recorded
Phase 3	NCT00441051	Nov → Dec 2006	sunburn	Novartis	Completed	No outcome recorded
Phase 3	NCT00375934	Sep 2006 → Jan 2007	neuropathy, painful	Xanodyne Pharmaceuticals	Completed	Met primary
Phase 3	NCT00366444	Aug → Oct 2006	neuropathy, painful	Xanodyne Pharmaceuticals	Completed	Met primary
Phase 3	NCT00448110	May 2006 → Nov 2007	neuropathy, painful	Javelin Pharmaceuticals	Completed	Met primary
Phase 3	NCT00171652	May → Oct 2005	osteoarthritis	Novartis	Completed	No outcome recorded
Phase 3	NCT00171665	May → Dec 2005	osteoarthritis	Novartis	Completed	Met primary
Phase 3	NCT00171691	Oct 2004 → Jun 2006	osteoarthritis	Novartis	Completed	No outcome recorded
Phase 3	NCT00171678	Oct 2004 → Aug 2005	osteoarthritis, knee	Novartis	Completed	No outcome recorded
Phase 3	NCT00171626	Aug 2004 → Jun 2005	osteoarthritis, knee	Novartis	Completed	No outcome recorded
Phase 3	NCT00108992	Feb 2004 → Sep 2005	osteoarthritis, knee	Nuvo Research Inc.	Completed	No outcome recorded
Phase 3	NCT00092378	Sep → Dec 2003	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00140933	Apr 2003 → ?	—	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 3	NCT00092742	Feb 2003 → Dec 2005	rheumatoid arthritis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00250445	Jan 2003 → May 2006	arthritic joint disease	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00092703	Jun 2002 → Nov 2003	osteoarthritis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00139646	Apr 2002 → Apr 2004	—	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00542087	Mar → Dec 2002	osteoarthritis	Organon and Co	Completed	No outcome recorded

Phase 453 trials · 3 met primary · 4 missed
Phase 4	NCT07565012	Oct 2025 → Mar 2026	periapical periodontitis, pulpitis	Armed Forces Institute of Dentistry, Pakistan	Completed	No outcome recorded
Phase 4	NCT07379762	Feb → Jul 2025	—	CMH Multan Institute of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT06379893	Apr → Oct 2024	—	HALEON	Completed	Mixed
Phase 4	NCT05761015	Dec 2023 → Apr 2028 expected	chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee	University Hospital, Clermont-Ferrand	Recruiting	No outcome recorded
Phase 4	NCT05211154	May 2022 → Apr 2025	migraine with aura, migraine without aura	Danish Headache Center	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT06231043	Apr 2022 → Mar 2023	—	Lampang Hospital	Completed	No outcome recorded
Phase 4	NCT05188131	Oct → Dec 2021	hypopituitarism	A.O.U. Città della Salute e della Scienza	Completed	No outcome recorded
Phase 4	NCT04585438	Sep 2021 → Sep 2022	pulpitis	Cairo University	Unknown	No outcome recorded
Phase 4	NCT05488925	Jun 2021 → Feb 2022	pulpitis	Farjad Zafar	Completed	Met primary
Phase 4	NCT04611529	Mar 2021 → Jun 2023	—	Montefiore Medical Center	Completed	Missed primary
Phase 4	NCT04608981	Mar → Dec 2021	pulpitis	Cairo University	Unknown	No outcome recorded
Phase 4	NCT07696104	Oct 2020 → May 2024	cystoid macular edema	Pomeranian Medical University Szczecin	Completed	No outcome recorded
Phase 4	NCT05433428	Aug 2020 → Jan 2023	cataract, dry eye syndrome	Ifocus Oyeklinikk	Unknown	No outcome recorded
Phase 4	NCT04054830	Aug 2019 → Jun 2022	glaucoma	Rigshospitalet, Denmark	Unknown	Missed primary
Phase 4	NCT03861611	Jul 2019 → Feb 2021	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT03781544	Jan 2019 → Jul 2025	osteoarthritis	University of Zurich	Unknown	No outcome recorded
Phase 4	NCT04050644	Oct 2018 → Jun 2024	senile cataract	Universitaire Ziekenhuizen KU Leuven	Unknown	No outcome recorded
Phase 4	NCT03605914	Aug 2018 → Jul 2020	—	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT03472339	Jan → Apr 2018	—	Hamad Medical Corporation	Unknown	No outcome recorded
Phase 4	NCT03745599	Nov 2017 → Sep 2018	—	Near East University, Turkey	Completed	No outcome recorded
Phase 4	NCT02826031	Apr 2016 → Oct 2017	osteoarthritis, knee	Kunming Baker Norton Pharmaceutical Sales Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT02714231	Mar 2016 → Feb 2017	—	Assiut University	Completed	No outcome recorded
Phase 4	NCT03221946	Jan 2016 → Sep 2017	—	Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre	Completed	No outcome recorded
Phase 4	NCT02664116	Jan 2016 → Jul 2017	migraine disorder	Scripps Health	Unknown	No outcome recorded
Phase 4	NCT02287376	Jan 2015 → Feb 2016	migraine disorder	Depomed	Completed	No outcome recorded
Phase 4	NCT02287350	Sep 2014 → Jan 2016	—	Depomed	Completed	No outcome recorded
Phase 4	NCT02547896	Sep 2014 → Jun 2015	impacted teeth, multiple	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT02187614	Aug 2014 → Feb 2015	urolithiasis	Hamad Medical Corporation	Completed	Met primary
Phase 4	NCT02132247	May 2014 → Oct 2016	—	IBSA Institut Biochimique SA	Completed	No outcome recorded
Phase 4	NCT02445599	Apr 2014 → Apr 2016	lung disorder	University of Debrecen	Completed	No outcome recorded
Phase 4	NCT01982539	Nov 2013 → May 2014	—	Depomed	Completed	No outcome recorded
Phase 4	NCT01935531	Jun 2013 → Jan 2016	actinic keratosis	University Hospital Regensburg	Completed	No outcome recorded
Phase 4	NCT02253446	May 2013 → Jul 2014	primary dysmenorrhea	Pamukkale University	Completed	No outcome recorded
Phase 4	NCT01907984	Dec 2012 → Apr 2013	—	University of Debrecen	Completed	No outcome recorded
Phase 4	NCT01666197	Aug 2012 → Jan 2013	—	Novartis	Completed	No outcome recorded
Phase 4	NCT01039545	Feb 2012 → Dec 2014	urinary tract infection	Insel Gruppe AG, University Hospital Bern	Terminated	Missed primary
Phase 4	NCT02779530	Oct 2011 → Jul 2013	drug-induced mental disorder	Eduardo Barbosa Coelho	Completed	No outcome recorded
Phase 4	NCT01383954	Jun 2011 → Aug 2012	osteoarthritis, knee	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 4	NCT01335724	Apr → Jul 2011	—	Novartis	Completed	Met primary
Phase 4	NCT01257126	Apr → Dec 2011	respiratory tract infectious disorder	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT02961855	Jan 2011 → Jan 2013	anal fistula, hemorrhoid	Hospital de Viladecans	Completed	No outcome recorded
Phase 4	NCT01454791	Jan 2011 → Mar 2013	multiple sclerosis	Brown, Theodore R., M.D., MPH	Completed	Missed primary
Phase 4	NCT01211431	Sep 2010 → Oct 2012	—	Nîmes University Hospital	Withdrawn	No outcome recorded
Phase 4	NCT01019980	Mar 2010	—	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT01054820	Jan → Mar 2010	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT00792376	Aug 2009 → Dec 2011	disease of the tendon	Argentine Tennis Association	Completed	No outcome recorded
Phase 4	NCT00491192	Jun 2007 → Jun 2009	subarachnoid hemorrhage, traumatic brain injury	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	Unknown	No outcome recorded
Phase 4	NCT00140972	Dec 2004 → Jun 2005	osteoarthritis	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00090181	Jun 2004 → Mar 2005	chronic pain syndrome	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00140920	May → Sep 2004	—	Merck Sharp & Dohme LLC	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00174317	Aug 2003 → Feb 2005	osteoarthritis, hip	Pfizer	Completed	No outcome recorded
Phase 4	NCT00377806	Jan 2003 → Sep 2006	thrombophlebitis	Novartis	Completed	No outcome recorded
Phase 4	NCT02181920	Mar → Nov 2000	—	Boehringer Ingelheim	Terminated	No outcome recorded

Phase not applicable41 trials · 3 missed
—	NCT07101016	Aug 2025 overdue	periapical periodontitis	Mariam Hesham Mahmoud Abdelfattah Eissa	Not yet recruiting	No outcome recorded
—	NCT07646093	May 2025	—	Hospital Universitario de Caracas	Completed	No outcome recorded
—	NCT06954181	Mar → Apr 2025	—	HALEON	Completed	No outcome recorded
—	NCT06905561	Feb 2025 → Jun 2026 overdue	breast cancer, head and neck neoplasm	The Second Affiliated Hospital of Hainan Medical University	Recruiting	No outcome recorded
—	NCT06574191	Jan 2025 → Jan 2028 expected	osteoarthritis, knee	University of California, Davis	Recruiting	No outcome recorded
—	NCT07203651	Jan → Jun 2025 overdue	—	Pakistan Institute of Medical Sciences	Active not recruiting	No outcome recorded
—	NCT06453291	Jul 2024 → Apr 2025 overdue	chronic pain syndrome	Iffat Anwar Medical Complex	Recruiting	No outcome recorded
—	NCT06937853	May 2024 → Jul 2025 overdue	—	Ataturk University	Recruiting	No outcome recorded
—	NCT06632015	Jan → May 2024	acute apical periodontitis	Mustafa Kemal University	Completed	No outcome recorded
—	NCT06307106	Jan → Oct 2024	—	Zagazig University	Completed	No outcome recorded
—	NCT06186921	Dec 2023 → Mar 2024	pulpitis	Jamia Millia Islamia	Unknown	No outcome recorded
—	NCT05947461	Jun 2023 → Jun 2024	acute pancreatitis	Air Force Military Medical University, China	Terminated	Missed primary
—	NCT06710600	Sep 2022 → Apr 2024	photosensitivity disease	Medical University of Vienna	Completed	No outcome recorded
—	NCT07267182	Aug 2022 → Feb 2023	—	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT05322603	Mar → Aug 2022	—	Petrovsky National Research Centre of Surgery	Completed	No outcome recorded
—	NCT04593160	Mar 2022 → Oct 2024	pulpitis	Cairo University	Completed	No outcome recorded
—	NCT06845930	Apr → Sep 2021	—	Assumpta Nnenna Nweke	Completed	No outcome recorded
—	NCT04622488	Nov 2020 → Jul 2022	—	Cairo University	Unknown	No outcome recorded
—	NCT04592016	Oct 2020 → Aug 2021	—	Joanneum Research Forschungsgesellschaft mbH	Completed	No outcome recorded
—	NCT04511832	Mar 2018 → Dec 2021	breast cancer	China Medical University Hospital	Completed	No outcome recorded
—	NCT03409874	Feb 2018 → Jul 2020	temporomandibular joint dysfunction syndrome	Alabama Physical Therapy & Acupuncture	Completed	No outcome recorded
—	NCT03518463	Jun → Jul 2017	pregnancy disorder	Mbarara University of Science and Technology	Completed	No outcome recorded
—	NCT03116672	Feb 2016 → Feb 2017	pulpitis	Universidad Autonoma de Baja California	Completed	No outcome recorded
—	NCT03269591	Feb → Sep 2016	primary dysmenorrhea	Cairo University	Completed	No outcome recorded
—	NCT02665533	Jan 2016	—	Federal University of the Valleys of Jequitinhonha and Mucuri	Completed	No outcome recorded
—	NCT02440399	Jul 2015 → May 2017	—	HaEmek Medical Center, Israel	Completed	Missed primary
—	NCT02506348	Jul 2015 → Jan 2016	—	Wolfson Medical Center	Unknown	No outcome recorded
—	NCT02059018	Feb 2014 → Feb 2015	retinal ischemia	University of Aarhus	Completed	No outcome recorded
—	NCT01762306	Nov 2012 → Jun 2013	—	Mahidol University	Unknown	No outcome recorded
—	NCT01764048	Nov 2012 → Jan 2014	—	HaEmek Medical Center, Israel	Completed	No outcome recorded
—	NCT01694212	Oct 2012 → Oct 2016	cataract, diabetic retinopathy, macular retinal edema	Eye Clinic Medic Zuljan Jukic	Completed	No outcome recorded
—	NCT01717599	Aug 2012 → Aug 2013	pancreatitis	Yonsei University	Completed	Missed primary
—	NCT02087462	Jan 2012 → Apr 2014	intervertebral disk degenerative disorder	Chengdu University of Traditional Chinese Medicine	Unknown	No outcome recorded
—	NCT01246180	Oct → Dec 2010	—	Hospices Civils de Lyon	Completed	No outcome recorded
—	NCT00530387	Jul 2008 → Jul 2011	photoallergic dermatitis	NHS Tayside	Completed	No outcome recorded
—	NCT01009021	Mar 2008 → Mar 2009	—	University of Sao Paulo	Completed	No outcome recorded
—	NCT00536068	Aug 2006 → Aug 2007	vascular hemostatic disease	Kantonsspital Graubünden	Completed	No outcome recorded
—	NCT00471393	May 2006 → Apr 2007	osteoarthritis	University of Alberta	Completed	No outcome recorded
—	NCT00476593	Sep 2005 → Dec 2009	iridocyclitis, macular retinal edema	Norwegian University of Science and Technology	Completed	No outcome recorded
—	NCT00221052	Jun → Jul 2005	obesity disorder	TNO	Completed	No outcome recorded
—	NCT00226538	Aug 1999 → ?	—	Hadassah Medical Organization	Completed	No outcome recorded

Phase not stated1 trial
—	NCT01579890	—	osteoarthritis, hand	Mallinckrodt	Approved for marketing	No outcome recorded
Comparator or background therapy213 trials
Phase 0	NCT06029296 Comparator	Jul 2024 → Aug 2026 overdue	alcohol-related disorders	University of Maryland, Baltimore	Active not recruiting	No outcome recorded
Phase 0	NCT07016451 Background	Apr 2024 → Sep 2025	radiation cystitis	Ramathibodi Hospital	Completed	No outcome recorded
Phase 0	NCT05582421 Comparator	Dec 2022 → Oct 2023	dental pulp necrosis, periapical periodontitis	Cairo University	Unknown	No outcome recorded
Phase 1	NCT06752486 Comparator	Dec 2024 → May 2025 overdue	—	Research Institute of Ophthalmology, Egypt	Recruiting	No outcome recorded
Phase 1	NCT06636227 Comparator	Dec 2024 → Aug 2026	alcohol dependence	University of Maryland, Baltimore	Completed	No outcome recorded
Show all 213 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 12

Date	Issuer	Release
2022-12-01	Alembic Pharmaceuticals Ltd.	Regulatory 1st December, 2022, Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) , Diclofenac Sodium Topical Solution USP, 2% w/w.
2022-10-28	Hisamitsu Pharmaceutical Co., Inc.	Results HP-5000（経皮鎮痛消炎剤）の変形性膝関節症に対する米国第Ⅲ相比較臨床試験結果のお知らせ hisamitsu.co.jp ↗
2022-09-22	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w lupin.com ↗ it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Diclofenac Sodium Topical Solution USP, 2% w/w
2022-07-01	Alembic Pharmaceuticals Ltd.	Regulatory 29th July, 2022, Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Diclofenac Sodium Topical Gel, 3%.
2020-04-06	Perrigo Company	Regulatory Perrigo Announces FDA Approval for the Store Brand Equivalent of Voltaren® Arthritis Pain perrigo.com ↗ Perrigo Company plc (NYSE: PRGO; TASE) today announced that it was the first to receive approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for over-the-counter ("OTC") diclofenac sodium topical gel 1%.
2020-02-17	GlaxoSmithKline	Regulatory FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States gsk.com ↗ With the FDA’s approval, Voltaren Arthritis Pain becomes the first and only prescription strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the United States.
2019-12-01	Alembic Pharmaceuticals Ltd.	Regulatory 2nd December, 2019, Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diclofenac Sodium Topical Solution USP, 2% w/w.
2019-11-26	Hisamitsu Pharmaceutical Co., Inc.	Results HP-5000（経皮鎮痛消炎剤）の米国第Ⅱ相臨床試験結果のお知らせ hisamitsu.co.jp ↗
2019-05-21	Perrigo Company	Regulatory Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1% perrigo.com ↗ Perrigo Company plc (NYSE; TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren ® Gel, 1% (diclofenac sodium topical gel, 1%).
2014-12-02	Perrigo Company	Regulatory Perrigo Announces FDA Approval And Launch Of The Generic Version Of Pennsaid® 1.5% w/w perrigo.com ↗ DUBLIN , Dec. 2, 2014 / PRNewswire / -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for diclofenac sodium topical solution 1.5% w/w.
2013-10-30	Impax Laboratories, LLC	Regulatory Impax Laboratories and TOLMAR, Inc. Announce Final FDA Approval for Generic Solaraze® Gel (Diclofenac Sodium-3%) amneal.com ↗
2008-11-19	Pharmos	Results Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream pharmoscorp.com ↗ The study did not achieve statistical significance in its primary efficacy endpoint, nor in several secondary endpoints.

All press releases naming this drug 25 releases

Date	Issuer	Release
2026-03-31	HALEON	Voltaren Topical Products and UEFA Champions League Join Forces to Keep Fans Moving haleon.com ↗
2022-12-09	Lupin Limited	Lupin Launches Authorized Generic Version of PENNSAID® 2% w/w in the United States lupin.com ↗
2022-12-01	Alembic Pharmaceuticals Ltd.	1st December, 2022, Vadodara, India alembicpharmaceuticals.com ↗
2022-10-28	Hisamitsu Pharmaceutical Co., Inc.	HP-5000（経皮鎮痛消炎剤）の変形性膝関節症に対する米国第Ⅲ相比較臨床試験結果のお知らせ hisamitsu.co.jp ↗
2022-09-22	Lupin Limited	Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w lupin.com ↗
2022-07-01	Alembic Pharmaceuticals Ltd.	29th July, 2022, Vadodara, India alembicpharmaceuticals.com ↗
2021-05-05	Assertio Holdings, Inc	Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine) assertiotx.com ↗
2021-01-04	Hisamitsu Pharmaceutical Co., Inc.	HP-5000（経皮鎮痛消炎剤）の米国第Ⅲ相比較臨床試験開始のお知らせ hisamitsu.co.jp ↗
2020-10-08	Impax Laboratories, LLC	Amneal & PL Developments Launch Store Brand Program of Over-the-Counter (“OTC”) Diclofenac Sodium Topical Gel, 1% amneal.com ↗
2020-09-08	Perrigo Company	Perrigo Announces The Store Brand Equivalent Of Voltaren® Arthritis Pain Is Available At U.S. Major Retailers Nationwide perrigo.com ↗
2020-04-06	Perrigo Company	Perrigo Announces FDA Approval for the Store Brand Equivalent of Voltaren® Arthritis Pain perrigo.com ↗
2020-02-17	GlaxoSmithKline	FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States gsk.com ↗
2019-12-01	Alembic Pharmaceuticals Ltd.	2nd December, 2019, Vadodara, India alembicpharmaceuticals.com ↗
2019-11-26	Hisamitsu Pharmaceutical Co., Inc.	HP-5000（経皮鎮痛消炎剤）の米国第Ⅱ相臨床試験結果のお知らせ hisamitsu.co.jp ↗
2019-05-21	Perrigo Company	Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1% perrigo.com ↗
2019-03-01	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of an Authorized Generic of Flector® Patch (diclofenac epolamine topical patch) in the United States tevapharm.com ↗
2018-11-27	Perrigo Company	Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3% perrigo.com ↗
2017-09-25	Hisamitsu Pharmaceutical Co., Inc.	HP-5000（経皮鎮痛消炎剤）の米国第Ⅱ相比較臨床試験開始のお知らせ hisamitsu.co.jp ↗
2014-12-02	Perrigo Company	Perrigo Announces FDA Approval And Launch Of The Generic Version Of Pennsaid® 1.5% w/w perrigo.com ↗
2013-11-21	Impax Laboratories, LLC	Impax Laboratories Launches Generic Solaraze® (Diclofenac Sodium Gel, 3%) amneal.com ↗
2013-10-30	Impax Laboratories, LLC	Impax Laboratories and TOLMAR, Inc. Announce Final FDA Approval for Generic Solaraze® Gel (Diclofenac Sodium-3%) amneal.com ↗
2011-12-05	Almirall, S.A.	Almirall launches Solaraze® in Spain for the treatment of actinic keratosis almirall.com ↗
2008-11-19	Pharmos	Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream pharmoscorp.com ↗
2007-06-27	Pharmos	Pharmos Commences Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream pharmoscorp.com ↗
2000-02-22	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Pharmaceutical Industries Ltd. to Launch Generic Equivalent of Voltaren XR Immediately tevapharm.com ↗

Evidence & citations 61 cited values

Every value below carries the sentence it was read from. 449 sources stand behind the page.

Field	Value	Cited text
Known as	Diclofenac	“This study evaluated the proarrhythmic potential of hydroxypropyl-β-cyclodextrin (HPβCD)-diclofenac, a novel injectable diclofenac formulation solubilized with...” PMID 23578606 ↗ Apr 2013 358 “Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third...” NCT04050644 ↗ “(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has...” NCT05641246 ↗ “An Evaluator-blinded, Randomized Within-subject Repeat Insult Study to Evaluate Potential Skin Irritation and Sensitization of HP-5000 (Diclofenac Sodium Topical System) in...” NCT04882319 ↗ “Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)” NCT04067492 ↗ “Purpose: This is a randomized clinical trial comparing the effects of three different medications for acute low back pain (LBP):Ketorolac, Ibuprofen, Diclofenac” NCT03861611 ↗ “Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg” NCT01734954 ↗ “Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months” NCT04091022 ↗ “Diclofenac sodium gel in 3 different concentrations as- Diclofenac sodium 1%, 1.16% and 2.32% whichever was available in the given region.” NCT06379893 ↗ “The participants will receive non-steroidal anti- inflammatory drugs (NSAID), Diclofenac 20 mg/ day for 3 consecutive menstrual cycles.” NCT06976151 ↗ “Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.” NCT05507554 ↗ Show 348 more sources
Known as	AMZ001	“AMZ001 (Diclofenac Sodium Gel 3.06%)” NCT05968482 ↗ 1 “AMZ001 Diclofenac gel” NCT06693648 ↗
Known as	cataflam	“Diclofenac group, which received diclofenac 50 mg capsules (Cataflam) and placebo sprays.” NCT03745599 ↗ 4 “Drug: diclofenac sodium (cataflam)” NCT02714231 ↗ “oral diclofenac (Cataflam)” NCT00548678 ↗ NCT02674191 ↗ NCT07088042 ↗
Known as	DCS	“Diclofenac Sodium (DCS)” NCT06632015 ↗ 1 “Diclofenac Sodium (DCS)” NCT07506265 ↗
Known as	DF-ME	“DF-ME, which consists of 2% diclofenac sodium, was compounded according to the published instructions by RS Therapeutics Inc. (Canada) and stored in the same containers as SHT-ME.” NCT06184685 ↗
Known as	DIC075V	“intravenous diclofenac sodium (DIC075V) in adult volunteers” NCT00509743 ↗ 3 “Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels” NCT00448110 ↗ “Intravenous diclofenac sodium (DIC075V) 18.75 mg” NCT00474136 ↗ “intravenous diclofenac sodium (DIC075V)” NCT00548678 ↗
Known as	DICL-SR	“with Diclofenac Sodium Sustained Release Tablets (DICL-SR) 75mg, quaque die（QD）” NCT02826031 ↗
Known as	DICLO	“preservative-free dexamethasone (DEX), diclofenac (DICLO) eye drops” PMID 36602718 ↗ Jan 2023
Known as	Dicloabak	“Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye...” NCT04050644 ↗
Known as	Diclobene	“diclofenac (Diclobene) 100mg” NCT06710600 ↗
Known as	Diclofenac 50 mg oral tablet	“Diclofenac 50 mg oral tablet” NCT03506763 ↗
Known as	Diclofenac diethylamine 1.16% gel	“Drug: Diclofenac diethylamine 1.16% gel” NCT06729073 ↗
Known as	diclofenac epolamine	“A topical formulation of diclofenac (FLECTOR diclofenac epolamine topical system (FDETS)) is approved in adults for the treatment of acute pain due to minor strains, sprains,...” PMID 34826122 ↗ Nov 2021 2 “Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day” NCT04976088 ↗ “FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%” NCT01054820 ↗
Known as	Diclofenac Epolamine Patch	“Drug: Diclofenac Epolamine Patch” NCT03145259 ↗
Known as	Diclofenac hydroxyethylpyrrolidine	“Drug: Diclofenac hydroxyethylpyrrolidine” NCT01946984 ↗
Known as	Diclofenac Microemulsion	“Drug: Diclofenac Microemulsion” NCT06184685 ↗
Known as	Diclofenac Na	“Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.” NCT00476593 ↗ 1 “Diclofenac Na gel” NCT00601640 ↗
Known as	Diclofenac Na 0.1% Oph Soln	“Diclofenac Na 0.1% Oph Soln” NCT03597867 ↗
Known as	Diclofenac Potassium	“BACKGROUND: Diclofenac potassium for oral solution (CAMBIA®) may be an alternative for patients who would otherwise need to be seen in a healthcare setting for parenteral ketorolac.” PMID 31833000 ↗ Dec 2019 18 “The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours.” NCT06752486 ↗ “NSAIDs, Diclofenac Potassium in this study, is known as a drug which is effective for pain control and is as effective as coxib in acute pain management.” NCT01762306 ↗ “The tablets being tested will contain the drug, diclofenac potassium.” NCT02004301 ↗ “preoperative Diclofenac Potassium (50 mg Cataflam)” NCT03174860 ↗ “Diclofenac Potassium for Oral Solution 50 mg” NCT02287376 ↗ “Oral diclofenac potassium 50 mg” NCT00474136 ↗ “Drug: Diclofenac potassium” NCT02476422 ↗ “Drug: Diclofenac Potassium” NCT02255045 ↗ NCT06298383 ↗ NCT02658799 ↗ Show 8 more sources
Known as	Diclofenac Sodium	“In a randomized, double-blind, placebo-controlled trial, men and women aged > or = 40 years diagnosed with primary OA in the dominant hand were randomly assigned to self-apply...” PMID 19648310 ↗ Jul 2009 89 “A Randomized, Double-blind, Multi-site, Comparator-controlled, Phase III Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Tramadol Hydrochloride and...” NCT03714672 ↗ “Diclofenac sodium gel (DSG) is one of the commonly used topical NSAIDs, which can provide local pain relief for patients with hand OA with reduced systemic exposure,...” NCT04402047 ↗ “From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks...” NCT02306031 ↗ “The objective of this study was to investigate the efficacy and safety of diclofenac sodium 2% topical solution BID versus vehicle control solution for treating pain associated...” PMID 26506138 ↗ Nov 2015 “An Evaluator-blinded, Randomized Within-subject Repeat Insult Study to Evaluate Potential Skin Irritation and Sensitization of HP-5000 (Diclofenac Sodium Topical System) in...” NCT04882319 ↗ “Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.” NCT00640705 ↗ “Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.” NCT00640939 ↗ “OBJECTIVE: To evaluate the safety and efficacy of topical diclofenac sodium 1% gel (DSG) versus vehicle in patients aged 25-64 or ≥65 years who have been diagnosed with knee OA.” PMID 21174485 ↗ Jan 2011 “Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications” NCT04585334 ↗ “Objective: To compare the analgesic effectiveness of diclofenac sodium, bupivacaine or bupivacaine plus diclofenac sodium infiltrating wound appendectomies.” NCT02752971 ↗ Show 79 more sources
Known as	Diclofenac sodium gel	“Drug: Diclofenac sodium gel” NCT06729073 ↗
Known as	diclofenac sodium solution	“Drug: diclofenac sodium solution” NCT03145259 ↗
Known as	diclofenac-cholestyramine	“continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily” NCT00715091 ↗
Known as	Dicloftil	“Diclofenac Na 0.1% Oph Soln, "Dicloftil®", NSAID eyedrops administered three days before surgery” NCT03597867 ↗
Known as	Diclophenac	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00893854 ↗ 2 NCT02339428 ↗ NCT00226538 ↗
Known as	Diclophenac Potassium	“Diclophenac Potassium” NCT02663050 ↗
Known as	diclophenac sodium	“Patients will be given 100mg p.o. diclophenac sodium tablets” NCT02339428 ↗ 1 NCT04110119 ↗
Known as	DIEP	“Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day” NCT04976088 ↗
Known as	diklofenak	“Preservative free Diklofenak 1mg/mL drops (Voltaren minims) four times a day from three days before surgery.” NCT05433428 ↗ 1 “Bu dönemde NRS 4 ve üzerinde olması durumunda intramuskuler 75 mg diklofenak sodyum uygulanacaktır.” NCT07834502 ↗
Known as	diklofenak sodyum	“Bu dönemde NRS 4 ve üzerinde olması durumunda intramuskuler 75 mg diklofenak sodyum uygulanacaktır.” NCT07834502 ↗ 1 NCT07002788 ↗
Known as	DIV075V	“Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery” NCT00507026 ↗
Known as	DPSGC	“Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC; Zipsor*) is a novel formulation of diclofenac potassium used to treat mild to moderate acute pain.” PMID 22587481 ↗ Jun 2012 1 “Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) is a rapid” PMID 19922878 ↗ Oct 2009
Known as	drug: diclofenac sodium	“drug: diclofenac sodium” NCT04341402 ↗
Known as	DSG	“The purpose of this study is to evaluate the efficacy of Diclofenac Sodium Topical (DSG) 1% compared with placebo applied four times a day in subjects with acute ankle sprains...” NCT01255423 ↗ 5 “Diclofenac sodium gel (DSG) is one of the commonly used topical NSAIDs, which can provide local pain relief for patients with hand OA with reduced systemic exposure,...” NCT04402047 ↗ “OBJECTIVE: To evaluate the safety and efficacy of topical diclofenac sodium 1% gel (DSG) versus vehicle in patients aged 25-64 or ≥65 years who have been diagnosed with knee OA.” PMID 21174485 ↗ Jan 2011 “Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness (DOMS) of the Lower Limbs” NCT02271854 ↗ “Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily” NCT01272934 ↗ “topical diclofenac sodium 1% gel (DSG)” PMID 22030938 ↗ Sep 2011
Known as	Dyloject	“injectable diclofenac sodium, Dyloject®, is solubilized with hydroxypropyl β-cyclodextrin (HPβCD)” PMID 22886837 ↗ Aug 2012
Known as	FDETS	“A topical formulation of diclofenac (FLECTOR diclofenac epolamine topical system (FDETS)) is approved in adults for the treatment of acute pain due to minor strains, sprains,...” PMID 34826122 ↗ Nov 2021
Known as	FLECTOR	“FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%” NCT01054820 ↗
Known as	HP-5000	“An Evaluator-blinded, Randomized Within-subject Repeat Insult Study to Evaluate Potential Skin Irritation and Sensitization of HP-5000 (Diclofenac Sodium Topical System) in...” NCT04882319 ↗
Known as	HPβCD-diclofenac	“This study evaluated the proarrhythmic potential of hydroxypropyl-β-cyclodextrin (HPβCD)-diclofenac, a novel injectable diclofenac formulation solubilized with...” PMID 23578606 ↗ Apr 2013 1 “Hydroxypropyl-β-cyclodextrin-diclofenac (HPβCD-diclofenac) is an NSAID used to treat acute moderate-to-severe postoperative pain.” PMID 29492863 ↗ Mar 2018
Known as	Hydroxypropyl-β-cyclodextrin-diclofenac	“Hydroxypropyl-β-cyclodextrin-diclofenac (HPβCD-diclofenac) is an NSAID used to treat acute moderate-to-severe postoperative pain.” PMID 29492863 ↗ Mar 2018
Known as	Itami	“Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications” NCT04585334 ↗
Known as	LAS41007	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00991861 ↗ 1 NCT01265602 ↗
Known as	Pennsaid	“Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis” NCT01579890 ↗ 3 NCT01508676 ↗ NCT01350622 ↗ NCT01511939 ↗
Known as	PENNSAID Gel	“PENNSAID Gel is a new topical gel formulation of diclofenac sodium that is similar in composition to PENNSAID solution.” NCT01202799 ↗
Known as	Sodium diclofenac	“Drug: Sodium diclofenac” NCT02752971 ↗
Known as	Solaraze	“To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera...” NCT01962987 ↗ 6 “Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months” NCT04091022 ↗ “using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp” NCT01453179 ↗ “Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.” NCT01742663 ↗ “Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharmaceuticals Inc.)” NCT03826550 ↗ “Solaraze® (Diclofenac sodium) 2x/day topical for 3 months” NCT00204542 ↗ NCT04552327 ↗
Known as	SoluMatrix Diclofenac	“Low-dose SoluMatrix® diclofenac has been developed to provide efficacy at lower diclofenac doses.” PMID 25913498 ↗ Apr 2015 1 “SoluMatrix® Diclofenac: Sustained Opioid-Sparing Effects in a Phase 3 Study” PMID 26995799 ↗ Mar 2016
Known as	TDS-943	“TDS-943 (topical diclofenac sodium 4% spray)” NCT00546832 ↗
Known as	Voltaren	“A Multi-Center, Double-Blind, Vehicle-Controlled, Parallel-Group Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%...” NCT02121002 ↗ 19 “Voltaren®, 50 mg soluble tablets, was selected among other possible diclofenac products because with this formulation peak concentration of diclofenamic acid is achieved at...” NCT02495831 ↗ “(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has...” NCT05641246 ↗ “Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)” NCT04067492 ↗ “a product containing the non-steroidal anti-inflammatory drug diclofenac (Voltaren) on trapezius trigger point pain.” NCT03939884 ↗ “Diclofenac sodium: 1 mL of gel prepared by incorporating 1 mL of 3 mL/75 mg Voltaren into a 1% Carbopol 940 gel base” NCT07101016 ↗ “group II who will receive diclofenac 100mg (voltaren® 100, Novartis) 1 hour before the procedure” NCT02419651 ↗ “IM diclofenac sodium (75 mg amp) (Voltaren, Novartis Pharmaceuticals Corporation, Switzerland)” NCT04508894 ↗ “Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography” NCT02433418 ↗ “oral Voltaren sustained-release tablets (diclofenac) at 0.5 mg/kg twice daily.” NCT07613346 ↗ “diclofenac 50mg (voltaren®, Novartis) 1 hour before the procedure” NCT02425709 ↗ Show 9 more sources
Known as	Voltaren (Ophta SDU;Novartis Pharms) eye drops.	“Voltaren (Ophta SDU;Novartis Pharms) eye drops.” NCT00476593 ↗
Known as	voltaren 100	“group II who will receive oral diclofenac 100mg (voltaren® 100, Novartis) 1 hour before the procedure” NCT02428777 ↗
Known as	Voltaren Gel	“In a randomized, double-blind, placebo-controlled trial, men and women aged > or = 40 years diagnosed with primary OA in the dominant hand were randomly assigned to self-apply...” PMID 19648310 ↗ Jul 2009 1 “Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%” NCT02596451 ↗
Known as	Voltaren minims	“Preservative free Diklofenak 1mg/mL drops (Voltaren minims) four times a day from three days before surgery.” NCT05433428 ↗
Known as	Voltaren Ophta SDU;Novartis Pharms	“Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.” NCT00476593 ↗
Known as	Voltaren Ophtha	“Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye...” NCT04050644 ↗
Known as	Voltaren or Votalin.	“Voltaren or Votalin.” NCT02087462 ↗
Known as	Zipsor	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01982539 ↗
Action	Inhibit	“Diclophenac is a non-steroid anti-inflammatory drug that improves the vision and decreases the macular thickness by slowing down the prostaglandin E2 (PGE2) ending in vascular...” NCT00893854 ↗
Modality	Other / unclassified	“Diclofenac is a non steroidal anti inflammatory drug” NCT02425709 ↗
Route	Topical	“the patient will apply a topical solution to his/her osteoarthritic knee” NCT00108992 ↗
Target	PPARG	“diclofenac has been shown to interact with PPAR-gamma in physiological concentrations and to antagonise PPAR-gamma mediated effects like adipogenesis” NCT01458600 ↗